oxatomide has been researched along with Chronic Disease in 8 studies
oxatomide: structure; an anti-allergic & an anti-asthmatic
oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy and tolerability of cetirizine in patients with idiopathic chronic urticaria to the more widely used antihistamine, oxatomide." | 9.09 | Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. ( Barberio, G; Corrias, A; Grimaldi, I; La Rosa, M; Leonardi, S; Marchese, G; Oggiano, N, 2001) |
| " In Japan, no study has been performed to determine whether orally administered oxatomide, H1 antihistamine, can reduce the chronic cough seen in patients with post-upper-airway infection (postinfection)." | 9.08 | [Effects of oxatomide, H1-antagonist, on postinfectious chronic cough; a comparison of oxatomide combined with dextromethorphan versus dextromethorphan alone]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1998) |
| "A new type of antiallergic drug, oxatomide (60 mg daily), was compared with the antihistaminic, mequitazine (10 mg daily), in a 5-week double-blind randomized study involving 26 patients with chronic urticaria." | 9.05 | Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine. ( Broux, R; Demaubeuge, J; Tennstedt, D, 1982) |
| "Oxatomide was evaluated in a double-blind study of 35 patients with chronic urticaria." | 9.05 | Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial. ( Campaert, H; Mertens, RL; Morias, J; Peremans, W, 1981) |
| "Oxatomide (Tinset) is a new, powerful, antiallergic agent." | 6.67 | [Chronic urticaria: role of oxatomide]. ( Mestre-Deharo, C; Sayag, J, 1990) |
| "We compared the efficacy and tolerability of cetirizine in patients with idiopathic chronic urticaria to the more widely used antihistamine, oxatomide." | 5.09 | Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. ( Barberio, G; Corrias, A; Grimaldi, I; La Rosa, M; Leonardi, S; Marchese, G; Oggiano, N, 2001) |
| " In Japan, no study has been performed to determine whether orally administered oxatomide, H1 antihistamine, can reduce the chronic cough seen in patients with post-upper-airway infection (postinfection)." | 5.08 | [Effects of oxatomide, H1-antagonist, on postinfectious chronic cough; a comparison of oxatomide combined with dextromethorphan versus dextromethorphan alone]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1998) |
| "A new type of antiallergic drug, oxatomide (60 mg daily), was compared with the antihistaminic, mequitazine (10 mg daily), in a 5-week double-blind randomized study involving 26 patients with chronic urticaria." | 5.05 | Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine. ( Broux, R; Demaubeuge, J; Tennstedt, D, 1982) |
| "Oxatomide was evaluated in a double-blind study of 35 patients with chronic urticaria." | 5.05 | Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial. ( Campaert, H; Mertens, RL; Morias, J; Peremans, W, 1981) |
| " Following the administration of oxatomide 1 mg/kg, the peak plasma concentration (Cmax), the elimination half-life (t1/2), the volume of distribution (Vd), and the area under the curve (AUC) 0-36 h were measured and the following results were obtained: 42." | 2.70 | Pharmacokinetics of oxatomide in preterm infants. ( Bertini, G; Ciuffi, M; Dani, C; Filippi, L; Martelli, E; Mazzetti, L; Pezzati, M; Rubaltelli, FF; Zilletti, L, 2002) |
| "Oxatomide (Tinset) is a new, powerful, antiallergic agent." | 2.67 | [Chronic urticaria: role of oxatomide]. ( Mestre-Deharo, C; Sayag, J, 1990) |
| "Postinfectious cough has been drawing attention as a factor involved in the etiology of chronic cough in the United States." | 1.30 | [Clinical features of postinfectious chronic cough]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dani, C | 1 |
| Martelli, E | 1 |
| Bertini, G | 1 |
| Filippi, L | 1 |
| Pezzati, M | 1 |
| Mazzetti, L | 1 |
| Ciuffi, M | 1 |
| Zilletti, L | 1 |
| Rubaltelli, FF | 1 |
| Demaubeuge, J | 1 |
| Tennstedt, D | 1 |
| Broux, R | 1 |
| Peremans, W | 1 |
| Mertens, RL | 1 |
| Morias, J | 1 |
| Campaert, H | 1 |
| Fujimori, K | 2 |
| Suzuki, E | 2 |
| Arakawa, M | 2 |
| La Rosa, M | 1 |
| Leonardi, S | 1 |
| Marchese, G | 1 |
| Corrias, A | 1 |
| Barberio, G | 1 |
| Oggiano, N | 1 |
| Grimaldi, I | 1 |
| Mestre-Deharo, C | 1 |
| Sayag, J | 1 |
| Pigatto, PD | 1 |
| Nicora, M | 1 |
| Altomare, GF | 1 |
| Morelli, M | 1 |
| Finzi, AF | 1 |
6 trials available for oxatomide and Chronic Disease
| Article | Year |
|---|---|
Pharmacokinetics of oxatomide in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Chronic Disease; Half-Life; Histamine H1 | 2002 |
Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine.
Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists; Hum | 1982 |
Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1981 |
[Effects of oxatomide, H1-antagonist, on postinfectious chronic cough; a comparison of oxatomide combined with dextromethorphan versus dextromethorphan alone].
Topics: Adult; Antitussive Agents; Chronic Disease; Common Cold; Cough; Dextromethorphan; Drug Therapy, Comb | 1998 |
Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children.
Topics: Anti-Allergic Agents; Cetirizine; Child, Preschool; Chronic Disease; Double-Blind Method; Drug Toler | 2001 |
[Chronic urticaria: role of oxatomide].
Topics: Chronic Disease; Double-Blind Method; Histamine H1 Antagonists; Humans; Piperazines; Single-Blind Me | 1990 |
2 other studies available for oxatomide and Chronic Disease
| Article | Year |
|---|---|
[Clinical features of postinfectious chronic cough].
Topics: Adult; Aged; Antitussive Agents; Chronic Disease; Common Cold; Cough; Dextromethorphan; Drugs, Chine | 1997 |
[Oxatomide in the treatment of chronic urticaria: evaluation of its effectiveness and tolerance].
Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Histamine H1 | 1987 |